J7513 — Daclizumab, parenteral, 25 mg
J7513 is a HCPCS Level II code for daclizumab, parenteral, 25 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated J7513 on December 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J7513
- Long descriptor
- Daclizumab, parenteral, 25 mg
- Short descriptor
- Daclizumab, parenteral
- Added
- January 1, 1999
- Terminated
- December 31, 2025
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J7513
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J7513 is not quite right, the correct code is very often within a few positions of it.
- J7505Muromonab-cd3, parenteral, 5 mgterminated
- J7506Prednisone, oral, per 5 mgterminated
- J7507Tacrolimus, immediate release, oral, 1 mg
- J7508Tacrolimus, extended release, (astagraf xl), oral, 0.1 mg
- J7509Methylprednisolone oral, per 4 mg
- J7510Prednisolone oral, per 5 mg
- J7511Lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg
- J7512Prednisone, immediate release or delayed release, oral, 1 mg
- J7514Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
- J7515Cyclosporine, oral, 25 mg
- J7516Injection, cyclosporine, 250 mg
- J7517Mycophenolate mofetil, oral, 250 mg
- J7518Mycophenolic acid, oral, 180 mg
- J7519Injection, mycophenolate mofetil, 10 mg
- J7520Sirolimus, oral, 1 mg
- J7521Tacrolimus, granules, oral suspension, 0.1 mg
Questions about J7513
What is HCPCS code J7513?
J7513 is a HCPCS Level II code for daclizumab, parenteral, 25 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J7513?
The CMS HCPCS file marks J7513 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is J7513 still valid?
No. J7513 was terminated on December 31, 2025 and should not be used on new claims.